• News
  • SAN DIEGO
  • BioTech

Sorrento Therapeutics appoints Mark Durand to board

Sorrento Therapeutics Inc. (Nasdaq: SRNE) a San Diego late-stage clinical oncology company developing new treatments for cancer and associated pain, has added Mark W. Durand to its board of directors.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Sorrento Therapeutics Inc.

Company Website

6042 Cornerstone Ct. West Ste., B
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
SRNE
5.40
  -0.04  
- 0.74%
43,844,000
16.40
4.75

Sorrento Therapeutics Inc. Executive(s):

Henry Ji

  • Chief Executive Officer

Richard Vincent

  • Chief Financial Officer

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
SIC - 3728 - AIRCRAFT PARTS AND AUXILIARY EQUIPMENT, NOT ELSEWHERE CLASSIFIED
SIC - 3769 - GUIDED MISSILE AND SPACE VEHICLE PARTS AND AUXILIARY EQUIPMENT, N
SIC - 3721 - AIRCRAFT
SIC - 3761 - GUIDED MISSILES AND SPACE VEHICLES
SIC - 3724 - AIRCRAFT ENGINES AND ENGINE PARTS
Subscribe Today!